New drug approved for atopic dermatitis
Good news for all the sufferers of atopic dermatitis. Incyte pharmaceuticals new drug- ruxolitinib cream was approved ( https://investor.incyte.com/press-releases/press-releases/2021/Incyte-Announces-U.S.-FDA-Approval-of-Opzelura-ruxolitinib-Cream-a-Topical-JAK-Inhibitor-for-the-Treatment-of-Atopic-Dermatitis-AD/default.aspx ) by the FDA today (21st September 2021). OpzeluraTM is a topical cream whose active ingredient is a janus kinase inhibitor- ruxolitinib. The cream is approved for 12 years and older for topical short-term non-chronic and non-continuous use in patients who are not immuno-compromised. JAK-STAT pathway is a key cell signaling pathway involved in inflammation and itch.